Applications of (S)-3-Amino-4-(4-Bromophenyl)Butanoic Acid Hydrochloride in Industrial Manufacturing

As an original manufacturer, we supply (S)-3-Amino-4-(4-Bromophenyl)Butanoic Acid Hydrochloride for specialty synthesis in advanced pharmaceutical, biotechnological, and chemical industries. Our material integrates into high-value downstream production where stereochemistry, purity, and compliance drive results in regulated and innovation-focused markets. Below we highlight key industrial applications, detailed for real-world process compatibility and standards adherence.

1. Active Pharmaceutical Ingredient (API) Intermediate for Anticonvulsant Drugs

Pharmaceutical manufacturers use this chiral amino acid derivative as a core intermediate in the synthesis of modern anticonvulsant APIs, where enantiomeric excess and controlled impurity profiles are essential. The material introduces the critical bromophenyl moiety at the protected amino acid stage, forming the building block for structurally specific drug actives. Manufacturers run GMP-validated processes for the quality assurance needed in regulatory filings and global clinical supply chains.

Industry compliance standards

• ICH Q7: Good Manufacturing Practice for Active Pharmaceutical Ingredients
• EU GMP Part II (APIs Production)
• USP-NF, EP, JP (Pharmaceutical relevant monographs as applicable)
• 21 CFR Part 211

Typical usage ratio

• 0.8–1.2 mole equivalents relative to target API synthesis step; actual ratio set by yield optimization and downstream stereocontrol

Downstream process integration

• Introduced post-resolution as a primary precursor prior to cyclization, coupling, or reduction steps in multi-step batch or flow synthesis of drug substances

Final product types

• Oral solid dose APIs (e.g. novel and generic anticonvulsants)
• Parenteral drug actives
• Pharmaceutical grade intermediates for advanced manufacturing

2. Chiral Building Block for Peptide and Peptidomimetic Synthesis

Custom peptide contract manufacturing organizations employ this enantiomerically pure amino acid salt in solid-phase or solution-phase synthesis of bioactive peptides where a brominated aromatic group is critical for receptor-selective binding. The hydrochloride salt enhances process solubility and handling in automated synthesizers and high-throughput flow lines.

Industry compliance standards

• ISO 9001:2015 (Quality Management for Peptide Synthesis)
• ICH Q11 (Development and Manufacture of Drug Substances)
• FDA 21 CFR Part 210, 211 (where peptides are intended as APIs or research actives)
• Peptide purity: >98% by HPLC as per customer QC

Typical usage ratio

• 1.0 equivalent per incorporation into peptide sequence; may use slight excess depending on coupling efficiency and process yield

Downstream process integration

• Loaded onto resin or introduced in solution at the sequence-specific position, followed by Fmoc deprotection, activation, and peptide elongation

Final product types

• Therapeutic peptide candidates
• Peptidomimetic research compounds
• Custom peptide libraries for screening

3. Intermediate for Synthesis of CNS-Active Research Chemicals

Contract research organizations and medicinal chemistry labs employ this compound in the preparation of brominated derivatives targeted for central nervous system research. The precise (S)-enantiomer enables downstream synthesis of analogues for screening and SAR (structure–activity relationship) studies, directly impacting early-stage pipeline development for neurological and psychiatric targets.

Industry compliance standards

• OECD GLP (Good Laboratory Practice for Test Facility Operation)
• ISO 17025 (Analytical Testing Quality)
• Controlled Substances legislation as applies to country/region of research output

Typical usage ratio

• Stoichiometric quantities, 0.9–1.1 equivalents relative to desired CNS-active scaffold in small-scale or pilot-scale syntheses

Downstream process integration

• Coupled in the initial or secondary step as an amine- or acid-donating component in route to analogues for lead optimization

Final product types

• CNS-active research compounds for preclinical studies
• Screening libraries for receptor interaction
• Brominated scaffold analogues for pharmacological profiling

4. Raw Material for Stereoselective Fine Chemical Synthesis

Manufacturers specializing in advanced fine chemicals exploit the chiral purity and robust reactivity of the compound in asymmetric synthesis, enabling selective construction of performance molecules used in specialty catalysts, advanced agrochemicals, and optically active ligands. The product’s HCl salt form ensures improved stability and metered addition under industrial process conditions.

Industry compliance standards

• ISO 9001:2015-certified chemical manufacturing processes
• REACH registration (EC No. 1907/2006) for chemical handling and supply into Europe
• Documented CoA and MoA for batch traceability

Typical usage ratio

• 0.5–1.5 equivalents depending on downstream asymmetric transformation; scaled per reaction stoichiometry and process containment limits

Downstream process integration

• Charged at stage-specific points for C–N bond formation, amide synthesis, or nucleophilic substitution in multistep fine chemical campaigns

Final product types

• Stereoenriched performance chemicals
• Chiral catalysts
• Synthetic intermediates for industrial research pipelines

5. Precursor for Functionalized Benzyl Derivatives in Material Science

Advanced materials laboratories utilize this compound during synthesis of functionalized aromatic derivatives where the bromine-substituted ring supports downstream cross-coupling for electronic, polymer, or sensor material research. The amino acid framework provides anchoring positions for further modification, important for controlling polymer backbone properties and material interactivity at the molecular level.

Industry compliance standards

• ISO 9001:2015 for advanced materials R&D supply
• Material Safety Data Sheet (GHS/CLP compliant)
• REACH compliant for use in laboratory-scale prototyping in Europe

Typical usage ratio

• 0.2–1.0 equivalents relative to final target compound, adjusted based on desired functional group density and polymer chain length

Downstream process integration

• Introduced as a functional monomer or as a substituent during aromatic modification or Suzuki-type cross-coupling, followed by purification and material casting or extrusion

Final product types

• Functionalized polymers
• Sensor coating agents
• Advanced research resins and electronic materials